Value is in the eye of the beholder. Yet, the value of game-changing medicines is coming under greater scrutiny in the U.S. marketplace than ever before. Companies are spending years developing drugs, only to arrive at commercialization and find disconnects with the very audiences they seek to serve. A well-defined value proposition for payers is no longer sufficient. Increasingly, developers must foster stakeholder expectations about the value of new medicines on the runway to commercialization. Leading biopharma executives, patient advocates and policy experts will provide perspectives on effective and compliant approaches to achieving shared views on value. Dialogue will reveal qualitative data on the resonance of different approaches to delivering value, from access initiatives to transparency pledges – and offer actionable insights for today’s developers.
Session ID: 413182